Adaptive Biotechnologies Corporation · NASDAQ:ADPT
Adaptive Biotechnologies — Cowen Liquid Biopsy Summit 2020
12 slides from Adaptive Biotechnologies's conference presentation, Sep 24, 2020
Slide 1: Cowen Liquid Biopsy Summit
Cowen Liquid Biopsy Summit September 24, 2020
Slide 2: Safe harbor
Safe harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co
Slide 3: The Adaptive Immune System
Detects & treats most diseases in exactly The Adaptive the same way Immune System SOLID TUM ORS Nature’s most INFECTIOUS AUTOIM M UNE DISORDERS DISEASE finely tuned diagnostic CNS LYM PHOID DISORDERS CANCERS 3
Slide 4: Translating the genetics of immune system into clinical products
Translating the genetics of immune system into clinical products One immune medicine Synergistic interplay with 3 High margin, immune driven platform business areas research and clinical products Life Science Clinical Drug Clinical Research Diagnostics Discovery Diagnostics COMMERCIAL IMMUNO- MRD SE
Slide 5: ADPT in context of “liquid biopsy”
ADPT in context of “liquid biopsy” Current Applications of Adaptive’s Approach Liquid Biopsy Look for tumor DNA circulating Identify/count T and B cells in blood in blood and other tissues T cell-based test for early and Detect cancer earlier (mostly solid immunoSEQ Dx accurate detection of many tum
Slide 6: clonoSEQ: monitoring MRD in blood cancer with unmatched accuracy
clonoSEQ: monitoring MRD in blood cancer with unmatched accuracy The technology Positioned to capture market share COUNTS Strong IP REMAINING CANCEROUS CELLS Significant evidence base FDA cleared Widely reimbursed Adopted by experts Deep Precise Robust sensitivity specificity validation Entrenched i
Slide 7: $4.5B market opportunity; clonoSEQ at early penetration stage
$4.5B market opportunity; clonoSEQ at early penetration stage Key Growth Levers Path to access 4.6M patients 1 Expand utilization in blood Grow evidence to support adoption 2 NHL across indications NHL 3 Increase payer coverage MM MMin blood in blood ALL ALLin blood in blood CLL in blood 4 Increase
Slide 8: clonoSEQ MRD testing opportunity in blood is nascent but promising
clonoSEQ MRD testing opportunity in blood is nascent but promising ALL in Blood CLL in Blood MRD positivity in blood highly correlated with Disease burden similar in blood and BM, making blood positivity in bone marrow (BM) 1 a reasonable substitute for MRD assessment in BM 2 clonoSEQ in Blood vs. F
Slide 9: immunoSEQ Dx: diagnostic answers for multiple diseases at the same time
immunoSEQ Dx: diagnostic answers for multiple diseases at the same time Solving a large but tractable Unleashing the potential to The applications problem with machine learning solve the ”diagnostic odyssey” Map trillions of TCRs to millions of clinically-relevant antigens of disease TCRs Lyme disea
Slide 10: T cells have potential to resolve diagnostic challenges in many diseases
T cells have potential to resolve diagnostic challenges in many diseases Why T – Cells Matter First T-cell based diagnostic Disease-specific T-Detect → better results versus current serology immunoSEQ Dx To be launched Fall 2020 Persistent SARS-CoV-2 Head to Head data: T-DETECT Multi- IgG serology s
Slide 11: immunoSEQ Dx: Disease selection & research stages through R&D pipeline
immunoSEQ Dx: Disease selection & research stages through R&D pipeline STAGE I STAGE II STAGE III STAGE IV STAGE V Prioritize Prepare for Identify Initial Develop Finalize Algo Diseases Modeling Signal Clinical Algo for Dev Market Sequence Achieve Initial Generate MVP Lock Algorithm Opportunity Samp
Slide 12: Slide 12
Adaptive Biotechnologies — Cowen Liquid Biopsy Summit 2020 on 6ix